Statins and Parkinson's: A complex interaction

Carroll, Camille; Wyse, Richard K.H.; Grosset, Donald G.

doi:10.1002/mds.27721

Cited by 5 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Contrary to these results, clinical trials and meta-analyses studies about the role of statins in PD remains controversial. Recent research highlighted the complexity of statins and PD showing that short-term use of statins were associated with an increased risk of PD, but the long-term use were not (214,215). However, in another recent meta-analysis, authors observed that statins can reduce the risk of PD, but concluded that additional randomized controlled trials and observational studies are necessary (216).…”

Section: Parkinson Diseasementioning

confidence: 99%

Repurposing statins for different pathologies. A jack-of-all-trades drug?

Rodrigues-Díez,

Tejera Muñoz,

Márquez-Expósito

et al. 2023

an.ranf

View full text Add to dashboard Cite

Apart from their well-stablished antihypercholesterolemic effect, HMG-CoA reductase inhibitors, commonly known as statins, have been described to exert pleotropic effects at different levels, including anti-inflammatory and pro-apoptotic responses. Since its discovery, and based on these properties, a broad range of studies have tried to evaluate their potential beneficial effects in other pathological situations beyond cardiovascular diseases (CVDs). Although statins effects have been evaluated in different types of diseases including not only in vitro and in vivo experiments, but also statin administration in patients, the current bibliography about statins is mainly focused on specific diseases and/or cell types. Hence, in this review, we aim to summarize every virtue attributed to statins in many pathologies, comprehending from the well-known effects in CVDs to the recent discovered beneficial effects in the COVID-19 disease, trough cancer, brain and autoimmune diseases or even pathogen infections. We include the suggested mechanisms implicated in these effects, the current situation of the use of statins in different pathologies as well as their negative and/or opposite effects stated by some authors. Considering the substantial cost and slow pace of new drugs discovery and development besides the high attrition rates, several authors have remarked the need of repurposing old drugs to treat common and rare diseases. Given the low risk, the low overall development costs and the short development timelines, the purpose of this review is to emphasize the potential use of statins as multitarget drug to treat different pathologies.

show abstract

Section: Parkinson Diseasementioning

confidence: 99%

Repurposing statins for different pathologies. A jack-of-all-trades drug?

Rodrigues-Díez,

Tejera Muñoz,

Márquez-Expósito

et al. 2023

an.ranf

View full text Add to dashboard Cite

show abstract

Section: Parkinson Diseasementioning

confidence: 99%

Untitled

2023

an.ranf

View full text Add to dashboard Cite

show abstract

“…Unfortunately, none of them was proved to stop or reverse this inevitable disease progression. Several clinical studies have shown that statins, the commonly-used lipid-lowering drugs could reduce the risk of PD ( Lin et al, 2016 ; Swallow et al, 2016 ; Brakedal et al, 2017 ; Kawada, 2017 ; Carroll et al, 2019 ). A double−blind randomized placebo−controlled clinical trial found that lovastatin treatment was associated with a slower exacerbation of motor symptoms in PD patients ( Lin et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

Lovastatin Alleviates α-Synuclein Aggregation and Phosphorylation in Cellular Models of Synucleinopathy

Dai

Wang

He³

et al. 2021

Front. Mol. Neurosci.

View full text Add to dashboard Cite

Parkinson’s disease (PD) is one of the most common neurodegenerative diseases. Pathologically, it is characterized by the aberrant aggregation of α-synuclein (α-syn) in neurons. Clinical evidence shows that patients with hypercholesterolemia are more likely to get PD, while lovastatin users have a lower risk of suffering from it. In this study, we investigated the effects of lovastatin on the aggregation and phosphorylation of α-syn in vitro. Our results demonstrate that α-syn preformed fibrils induce the phosphorylation and aggregation of α-syn in HEK293 cells stably transfected with α-syn-GFP and SH-SY5Y cells as well, which could be attenuated by in a concentration-dependent manner. Besides, lovastatin inhibited oxidative stress, histone acetylation, and the activation of casein kinase 2 (CK2). Collectively, lovastatin alleviates α-syn aggregation and phosphorylation in cellular models of synucleinopathy, indicating its potential value of being adopted in the management of PD.

show abstract

Statins and Parkinson's: A complex interaction

Cited by 5 publications

References 11 publications

Repurposing statins for different pathologies. A jack-of-all-trades drug?

Repurposing statins for different pathologies. A jack-of-all-trades drug?

Untitled

Lovastatin Alleviates α-Synuclein Aggregation and Phosphorylation in Cellular Models of Synucleinopathy

Contact Info

Product

Resources

About